R&D+i reveals all the potential value of FAES FARMA’s traditional vademecum, composed of innovative and high quality medicines, reinforcing our presence in the principal therapeutic areas and facilitating new synergic commercial agreements with other global pharmaceutical companies.
In this respect, FAES FARMA has focused on R&D+i for the development of new drugs that can offer clinical benefits in the therapeutic areas in which the company aims to achieve a position of leadership and in which it already has experience.
Resources and organisation
The Research Centre is staffed by around 70 highly qualified people, among which there are more than 40 university graduates. More than 14,000,000 euros were spent on R&D+i in 2017 and almost 3,000,000 euros invested in equipment.
Projects are carried out in the installations in Leioa (Bizkaia), in Avenida Autonomía 10, dedicating more than 4000 M2 to this work.
The R&D+i department is organised in three large areas: IDi API (R&D+i for Active Ingredients), IDi Farma (R&D+i for Development and Pharmaceutical Technologies) and IDi Clínica (Clinical R&D+i). Other valuable teams also collaborate in areas such as Project Management and R&D+I Promotion.
Exciting projects: FAES2020
FAES FARMA launched in January 2015 a Strategic Initiative called FAES2020 which defines the main strategic objectives in R& D+i for the next 5 years: the development of 20 novel medicines before the end of 2020. This initiative seeks not only to expand the supply of Bilastine products, but to extend its life cycle with new patents, to internationalize and to enlarge FAES FARMA portfolio, Moreover, there is a plan to develop a new chemical entity within the area that has given us so much success: Allergy.
The European approval in 2017 of paediatric bilastine in its oral solution and orodispersible tablet presentations
Following the lines of this Strategic Plan in R&D+i, FAES FARMA: